Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS CRP Rx · 1 trial · 1 indication
Burden measured as percentage of time spent in AF as derived from continuous pacemaker monitoring
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | ISIS CRP Rx followed by Placebo |
| Group B | EXPERIMENTAL | Placebo followed by ISIS CRP Rx |
| Name | Type | Description |
|---|---|---|
| ISIS CRP Rx | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Male of female; age over 18 years * Dual chamber permanent pacemaker implanted * Confirmed diagnosis of paroxysmal atrial fibrillation with an AF burden of 1 to 50%, as derived from pacemaker diagnostic algorithms * Able to have pacemaker antiarrhythmic algorithms turned off f...
ISIS CRP Rx is an investigational drug being studied for the treatment of paroxysmal atrial fibrillation, a type of irregular heartbeat that comes and goes. It is in Phase 2 clinical development for this cardiovascular condition.
ISIS CRP Rx is a small molecule designed to target C-reactive protein (CRP), a marker of inflammation. By reducing CRP levels, it may help reduce inflammation that contributes to atrial fibrillation episodes. The exact mechanism is being evaluated in clinical trials.
ISIS CRP Rx is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical research to evaluate the drug's safety and efficacy.
ISIS CRP Rx is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 trial has been completed to assess its effects in patients with paroxysmal atrial fibrillation.
ISIS CRP Rx has been studied in a Phase 2 clinical trial registered as NCT01710852, titled 'Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation.' This randomized, double-blind, controlled trial enrolled 7 participants in the United Kingdom and has been completed.
ISIS CRP Rx is a specific investigational compound developed by Ionis Pharmaceuticals. It is not known to be marketed under any other names. Its development name reflects its targeting of C-reactive protein (CRP) for potential therapeutic use.